Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Waverley Pharma Inc V.WAVE

Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. Its primary focus is the PARP-1 program and secondary focus is the generic oncology injectable market in European Union, the United Kingdom (UK) and North America. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted it an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.


TSXV:WAVE - Post by User

Comment by Higherhopes2020on Jul 30, 2020 3:48pm
127 Views
Post# 31346111

RE:The 2 New aproved Drugs are former BIG Blockbusters

RE:The 2 New aproved Drugs are former BIG BlockbustersResearch is funded by Council of Canada (NSERC) under its Alliance COVID-19 Grants program.  
Waverley Pharma is granted exclusive worldwide intellectual property and commercial rights to any resulting products or technology developed under the Agreement in exchange for paying a royalty to the University of Manitoba on future sales of such products or technology.

known as Alimta (Eli Lilly) and Velcade (Takeda)  with those 2 generics our WAVE will hit profitablility very fast in the coming months the company is already now close to cash flow neutral .

About Pemetrexed ( Brand Alimta )

Pemetrexed is an injectable chemotherapy product used in the treatment of pleural mesothelioma and non-small cell lung cancer along with other indications. The Company has obtained marketing authorization for this product in numerous countries including Belgium, the Czech Republic, Germany, Ireland, the Netherlands, and the United Kingdom and is in the process of filing for market authorization in additional countries across Europe.

About Bortezomib ( Brand Velcade)

Bortezomib is an injectable chemotherapy product used to treat multiple myeloma and mantle cell lymphoma along with other indications. The Company has obtained marketing authorization for this product in numerous countries including Belgium, Denmark, France, Germany, Ireland, the Netherlands, Norway, Spain, Sweden and the United Kingdom and is in the process of filing for market authorization in additional countries across Europe.

[/quote]

<< Previous
Bullboard Posts
Next >>